HALO
HALOZYME THERAPEUTICS, INC.
Nasdaq: HALO · San Diego, CA · Healthcare
$68.41-1.16 (-1.67%)Closed
Market Cap$8.06B
Cash$133.8Mmost recent
Runwayprofitable
P/E (TTM)26.7EPS $2.56
52-Wk Range$47.91 – $81.23
Avg Volume2.1M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$68.41+76.7%
Pipeline
Drug candidates sponsored by HALOZYME THERAPEUTICS · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Hylenex | Healthy+1 more | Completed | 2006-10past | 3 | |
| Phase 4 | recombinant human hyaluronidase | Healthy+1 more | Completed | 2009-11past | 2 | |
| Phase 4 | Sham Injection | Type 1 Diabetes Mellitus | Completed | 2012-08past | 1 | |
| Phase 4 | Commercial Hylenex® recombinant (hyaluronidase human injection) | Type 1 Diabetes Mellitus | Completed | 2014-02past | 1 | |
| Phase 4 | Rapid Acting insulin with pre-treatment of rHuPH20 | Type 1 Diabetes Mellitus | Completed | 2014-02-27past | 1 | |
| Phase 4 | large protein molecule | Rheumatoid Arthritis | Completed | — | 1 | |
| Phase 3 | Placebo | Pancreatic Ductal Carcinoma | Terminated | 2019-11-04past | 1 | |
| Phase 3 | Unnamed | Hypogonadism, Male | Recruiting | 2028-03 | 1 | |
| Phase 1 | Mitomycin C | Bladder Cancer | Completed | 2009-08-11past | 1 | |
| Phase 2 | rHuPH20 | Dermatitis, Allergic Contact+2 more | Completed | 2009-09-21past | 3 | |
| Phase 2 | Humalog | Type 1 Diabetes Mellitus+2 more | Completed | 2009-11past | 3 | |
| Phase 2 | Insulin Lispro | Diabetes Mellitus, Type 1+2 more | Completed | 2011-08past | 4 | |
| Phase 1 | Gemcitabine | Stage IV Pancreatic Cancer | Completed | 2014-02past | 1 | |
| Phase 2 | PEGPH20 | Metastatic Pancreatic Cancer+7 more | Completed | 2019-11-11past | 5 | |
| Phase 1 | Chemophase | Superficial Bladder Cancer | Completed | 2009-03past | 1 | |
| Phase 1 | Recombinant human hyaluronidase PH20 (rHuPH20) | Healthy | Completed | 2010-02past | 1 | |
| Phase 1 | Insulin aspart | Type 1 Diabetes Mellitus | Completed | 2011-12past | 1 | |
| Phase 1 | Ondansetron | Healthy | Completed | 2013-11past | 1 | |
| Phase 1 | PEGylated recombinant human hyaluronidase PH20 | Non-small Cell Lung Cancer | Terminated | 2016-08-09past | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for HALO. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.